The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
Open accessAbstract
FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) technology to examine 324 cancer genes in solid tumors. F1CDx reports known and likely pathogenic short variants (SVs), copy number alterations (CNAs), and select rearrangements, as well as complex biomarkers including tumor mutational burden (TMB) and microsatellite instability (MSI), in addition to genomic loss of heterozygosity (gLOH) in ovarian cancer. CGP services can reduce the complexity of biomarker testing, enabling precision medicine to improve treatment decision-making and outcomes for cancer patients, but only if test results are reliable, accurate, and validated clinically and analytically to the highest standard available. The analyses presented herein demonstrate the extensive analytical and clinical validation supporting the F1CDx initial and subsequent FDA approvals to ensure high sensitivity, specificity, and reliability of the data reported. The analytical validation included several in-depth evaluations of F1CDx assay performance including limit of detection (LoD), limit of blank (LoB), precision, and orthogonal concordance for SVs (including base substitutions [SUBs] and insertions/deletions [INDELs]), CNAs (including amplifications and homozygous deletions), genomic rearrangements, and select complex biomarkers. The assay validation of >30,000 test results comprises a considerable and increasing body of evidence that supports the clinical utility of F1CDx to match patients with solid tumors to targeted therapies or immunotherapies based on their tumor’s genomic alterations and biomarkers. F1CDx meets the clinical needs of providers and patients to receive guideline-based biomarker testing, helping them keep pace with a rapidly evolving field of medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Self-citationPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 1×
“alpelisib + fulvestrant [81, 82] SOLAR-1 clinical trial PIK3CA alterations (PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y) Breast cancer 93.”
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 3×
“FDA’s Center for Devices and Radiological Health [57] is responsible for establishing and ensuring quality standards by evaluating and regulating the performance of the companion diagnostics [58], particularly for high-risk testing services such as those for cancer genotyping PLOS ONE | https://doi.org/10.1371/journal…”
BackgroundMethodInfluentialOlaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 2×
“F1CDx is the result of the evolution of Foundation Medicine’s original FoundationOne(1) assay [64].”
BackgroundColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Allele-specific copy number analysis of tumors
Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,226
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Self-citationSurvival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
How to apply de Bruijn graphs to genome assembly
Compeau, P. E. C., Pevzner, P. A., & Tesler, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.2023 · Cited by 673
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0327 · Cited by 578
Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.3241 · Cited by 549
Self-citationPishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E., DeArbeloa, P., Hendifar, A., Mikhail, S., Chung, V., Sahai, V., Sohal, D. P. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30074-7 · Cited by 548
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 546
Merino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S.-J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000147 · Cited by 507
Self-citationKlempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 391
Self-citationHow liquid biopsies can change clinical practice in oncology
Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R. B., Siu, L. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz227 · Cited by 358
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
He, J., Abdel-Wahab, O., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J., Krivstov, A., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 311
Self-citationDouble PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I., Bell-McGuinn, K., Coleman, R. L., O'Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 281
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Sun, J. X., He, Y., Sanford, E., Montesion, M., Frampton, G. M., Vignot, S., Soria, J.-C., Ross, J. S., Miller, V. A., Stephens, P. J., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005965 · Cited by 273
Self-citationThe current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Pishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., Chung, V., Picozzi, V. J., Sohal, D., Blais, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0531 · Cited by 245
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 238
Bakry, D., Aronson, M., Durno, C., Rimawi, H., Farah, R., Alharbi, Q. K., Alharbi, M., Shamvil, A., Ben-Shachar, S., Mistry, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.005 · Cited by 233
An overview of precision oncology basket and umbrella trials for clinicians
Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K., & Mills, E. J. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21600 · Cited by 233
Trabucco, S. E., Gowen, K., Maund, S. L., Sanford, E., Fabrizio, D. A., Hall, M. J., Yakirevich, E., Gregg, J. P., Stephens, P. J., Frampton, G. M., et al. (2019) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.011 · Cited by 222
Self-citationRusch, M., Nakitandwe, J., Shurtleff, S., Newman, S., Zhang, Z., Edmonson, M. N., Parker, M., Jiao, Y., Ma, X., Liu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06485-7 · Cited by 213
NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
French, C. A. (2018) · Pathology International · doi:10.1111/pin.12727 · Cited by 210
Gutierrez, M. E., Choi, K., Lanman, R. B., Licitra, E. J., Skrzypczak, S. M., Pe Benito, R., Wu, T., Arunajadai, S., Kaur, S., Harper, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.004 · Cited by 208
Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
Ou, S. I., Zhu, V. W., & Nagasaka, M. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100015 · Cited by 187
Fontes Jardim, D. L., Schwaederle, M., Wei, C., Lee, J. J., Hong, D. S., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv253 · Cited by 186
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 182
Sokol, E. S., Pavlick, D., Khiabanian, H., Frampton, G. M., Ross, J. S., Gregg, J. P., Lara, P. N., Oesterreich, S., Agarwal, N., Necchi, A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00345 · Cited by 176
Self-citationMolecular Tumor Boards in Clinical Practice
Luchini, C., Lawlor, R. T., Milella, M., & Scarpa, A. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.008 · Cited by 175
Barbitoff, Y. A., Polev, D. E., Glotov, A. S., Serebryakova, E. A., Shcherbakova, I. V., Kiselev, A. M., Kostareva, A. A., Glotov, O. S., & Predeus, A. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59026-y · Cited by 173
Hampel, H., Pearlman, R., Beightol, M., Zhao, W., Jones, D., Frankel, W. L., Goodfellow, P. J., Yilmaz, A., Miller, K., Bacher, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0104 · Cited by 172
Freedman, A. N., Klabunde, C. N., Wiant, K. F., Enewold, L., Gray, S. W., Filipski, K. K., Keating, N. L., Leonard, D. G. B., Lively, T., McNeel, T. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00169 · Cited by 153
Ali, S. M., Hensing, T. A., Schrock, A. B., Allen, J. M., Sanford, E. M., Gowen, K. A., Kulkarni, A., He, J., Suh, J. H., Lipson, D., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0497 · Cited by 128
Self-citationHayes, D. F., Allen, J. D., Compton, C. C., Gustavsen, G. G., Leonard, D. G. B., Mccormack, R. T., Newcomer, L. N., Pothier, K. C., Ransohoff, D. F., Schilsky, R. L., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005950 · Cited by 124
Genetic Tests:Clinical Validity and Clinical Utility
Burke, W. (2014) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0915s81 · Cited by 117
Johnson, D. B., Dahlman, K. H., Knol, J., Gilbert, J., Puzanov, I. J., Means-Powell, J. A., Balko, J. M., Lovly, C. M., Murphy, B. A., Goff, L. W., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0011 · Cited by 116
Chmielecki, J., Ross, J. S., Wang, K., Frampton, G. M., Palmer, G. A., Ali, S. M., Palma, N. A., Morosini, D., Miller, V. A., Yelensky, R., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0234 · Cited by 113
Self-citationSuh, J. H., Johnson, A., Albacker, L. A., Wang, K., Chmielecki, J., Frampton, G. M., Gay, L. M., Elvin, J. A., Vergilio, J., Ali, S. M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0030 · Cited by 112
Self-citationDefining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint
Hayes, D. F. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01572 · Cited by 112
Haslem, D. S., Norman, S. B. V., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., Rhagunath, S., Newman, D. M., Gilbert, H., Tudor, B. P., et al. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011486 · Cited by 110
Ross, J. S., Gay, L. M., Wang, K., Ali, S. M., Chumsri, S., Elvin, J. A., Bose, R., Vergilio, J., Suh, J. H., Yelensky, R., et al. (2016) · Cancer · doi:10.1002/cncr.30102 · Cited by 97
Schwaederle, M., Daniels, G. A., Piccioni, D. E., Fanta, P. T., Schwab, R. B., Shimabukuro, K. A., Parker, B. A., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1061 · Cited by 90
Hirshfield, K. M., Tolkunov, D., Zhong, J., Ali, S. M., Stein, M. N., Murphy, S., Vig, H. S., Vázquez, A., Glod, J. W., Moss, R. A., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0049 · Cited by 87
Rozenblum, A. B., Ilouze, M., Dudnik, E., Dvir, A., Soussan‐Gutman, L., Geva, S., & Peled, N. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.021 · Cited by 84
Implementing Precision Medicine in Community-Based Oncology Programs: Three Models
Levit, L. A., Kim, E. S., McAneny, B. L., Nadauld, L. D., Levit, K., Schenkel, C., & Schilsky, R. L. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00661 · Cited by 84
Measuring coverage and accuracy of whole-exome sequencing in clinical context
Kong, S. W., Lee, I., Liu, X., Hirschhorn, J. N., & Mandl, K. D. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.51 · Cited by 81
Schrock, A. B., Welsh, A. W., Chung, J., Pavlick, D. C., Bernicker, E., Creelan, B., Forcier, B., Ross, J. S., Stephens, P. J., Ali, S. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.008 · Cited by 75
Self-citationNext-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
Ross, J. S., Wang, K., Rand, J. V., Gay, L. M., Presta, M., Sheehan, C. E., Ali, S. M., Elvin, J. A., LaBrecque, E., Hiemstra, C. N., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202514 · Cited by 74
Survivorship, Version 1.2021: Featured Updates to the NCCN Guidelines
Tevaarwerk, A. J., Denlinger, C. S., Sanft, T. B., Ansbaugh, S. M., Armenian, S. H., Baker, K. S., Broderick, G. A., Day, A., Demark‐Wahnefried, W., Dickinson, K. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0028 · Cited by 70
Gray, P. N., Dunlop, C. L. M., & Elliott, A. M. (2015) · Cancers · doi:10.3390/cancers7030837 · Cited by 68
Ross, J. S., Wang, K., Rand, J. V., Sheehan, C. E., Jennings, T. A., Al-Rohil, R. N., Otto, G. A., Curran, J. C., Palmer, G. A., Downing, S. R., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000102 · Cited by 64
The current landscape of the FDA approved companion diagnostics
Jørgensen, J. T. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101063 · Cited by 64
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options
Gay, L. M., Kim, S., Fedorchak, K., Kundranda, M. N., Odia, Y., Nangia, C. S., Battiste, J. D., Colón‐Otero, G., Powell, S. F., Russell, J. S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0287 · Cited by 63
Comprehensive genomic profiling of malignant phyllodes tumors of the breast
Nozad, S., Sheehan, C. E., Gay, L. M., Elvin, J. A., Vergilio, J., Suh, J. H., Ramkissoon, S. H., Schrock, A. B., Hirshfield, K. M., Ali, N. Ş. M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4156-1 · Cited by 61
A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology
Yip, S. S. F., Christofides, A., Banerji, S. O., Downes, M. R., Izevbaye, I., Lo, B., MacMillan, A., McCuaig, J. M., Stockley, T. L., Yousef, G. M., et al. (2019) · Current Oncology · doi:10.3747/co.26.4731 · Cited by 55
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Self-citationComprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Sigal, D. S., Bhangoo, M. S., Hermel, J. A., Pavlick, D. C., Frampton, G. M., Miller, V. A., Ross, J. S., & Ali, S. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26260 · Cited by 49
Self-citationSinger, C. F., Balmañà, J., Bürki, N., Delaloge, S., Filieri, M. E., Gerdes, A.-M., Grindedal, E. M., Han, S., Johansson, O., Kaufman, B., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.007 · Cited by 49
Rao, S., Pitel, B. A., Wagner, A. H., Boca, S. M., McCoy, M., King, I. F. G., Gupta, S., Park, B. H., Warner, J. L., Chen, J., et al. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00169 · Cited by 46
Kato, S., Kurasaki, K., Ikeda, S., & Kurzrock, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0199 · Cited by 45
Chawla, A., Jankú, F., Wheler, J. J., Miller, V. A., Ryan, J., Anhorn, R., Zhou, Z., & Signorovitch, J. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00074 · Cited by 44
Oncologist use and perception of large panel next-generation tumor sequencing
Schram, A. M., Reales, D. N., Galle, J., Cambria, R., Durany, R., Feldman, D. R., Sherman, E. J., Rosenberg, J. E., D’Andrea, G. M., Baxi, S. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx294 · Cited by 42
Challenges in the clinical implementation of precision medicine companion diagnostics
Keeling, P., Clark, J. J., & Finucane, S. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1757436 · Cited by 42
Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Rodríguez-Rodríguez, L., Hirshfield, K. M., Rojas, V. A., DiPaola, R. S., Gibbon, D. G., Hellmann, M., Isani, S. S., Leiser, A., Riedlinger, G., Wagreich, A. R., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.02.021 · Cited by 40
Ganesan, P., Moulder, S. L., Lee, J. J., Jankú, F., Valero, V., Zinner, R., Naing, A., Fu, S., Tsimberidou, A. M., Hong, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0358 · Cited by 38
Kopetz, S., Shaw, K. R. M., Lee, J. J., Zhang, J., Litzenburger, B. C., Holla, V. R., Kinyua, W. K., Broaddus, E., Daniels, M. S., Meric‐Bernstam, F., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00213 · Cited by 37
Occult Primary, Version 3.2014
Ettinger, D. S., Handorf, C. R., Agulnik, M., Bowles, D. W., Cates, J., Cristea, M. C., Dotan, E., Eaton, K. D., Fidias, P. M., Gierada, D. S., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0093 · Cited by 35
Signorovitch, J., Zhou, Z., Ryan, J., Anhorn, R., & Chawla, A. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1549056 · Cited by 35
MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
Fang, W., Zhou, H., Shen, J., Li, J., Zhang, Y., Hong, S., & Zhang, L. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000614 · Cited by 34
Reitsma, M., Fox, J., Borre, P. V., Cavanaugh, M., Chudnovsky, Y., Erlich, R., Gribbin, T. E., & Anhorn, R. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.18309 · Cited by 31
Should next-generation sequencing tests be performed on all cancer patients?
McKenzie, A. J., Dilks, H. H., Jones, S. F., & Burris, H. A. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1564043 · Cited by 31
Madison, R. W., Schrock, A. B., Castellanos, E. H., Gregg, J. P., Snider, J. W., Ali, S. M., Miller, V. A., Singal, G., Alexander, B. M., Venstrom, J. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.033 · Cited by 31
Ribeiro, T. B., Ribeiro, A., Rodrigues, L., Harada, G., & Nobre, M. R. C. (2019) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462319000813 · Cited by 28
Lee, H., Jabbour, T. E., Ainechi, S., Gay, L. M., Elvin, J. A., Vergilio, J., Suh, J. H., Ramkissoon, S. H., Ali, S. M., Schrock, A. B., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.10.007 · Cited by 27
Self-citationEmerging treatment options for ovarian cancer: focus on rucaparib
Mariappan, L., Jiang, X. Y., Jackson, J., & Drew, Y. (2017) · International Journal of Women s Health · doi:10.2147/ijwh.s151194 · Cited by 27
Cancer patients' expectations when undergoing extensive molecular diagnostics—A qualitative study
Rohrmoser, A., Pichler, T., Letsch, A., Westphalen, C. B., Keilholz, U., Heinemann, V., Goerling, U., & Herschbach, P. (2019) · Psycho-Oncology · doi:10.1002/pon.5282 · Cited by 25
Oulas, A., Minadakis, G., Zachariou, M., & Spyrou, G. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-39796-w · Cited by 24
Li, M. (2016) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2016.1202859 · Cited by 21
Oberg, J. A., Ruiz, J., Ali-Shaw, T., Schlechtweg, K., Ricci, A. M., Kung, A. L., Chung, W. K., Appelbaum, P. S., Bender, J. G., & Levine, J. M. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00104 · Cited by 20
Trivedi, H., Acharya, D., Chamarthy, U., Meunier, J., Al-Ahmad, H., Hamdan, M., Herman, J., & Srkalović, G. (2019) · Acta Medica Academica · doi:10.5644/ama2006-124.247 · Cited by 20
Huang, R. S. P., Haberberger, J., Sokol, E. S., Schrock, A. B., Danziger, N. A., Madison, R. W., Trabucco, S. E., Jin, D. X., Pavlick, D. C., Ramanan, V., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33447 · Cited by 20
Self-citationStanek, E. J., Sanders, C., & Frueh, F. W. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3020111 · Cited by 18
Powell, S. F., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M. A., Hack, K. M., Gitau, M. M., Steen, P. D., Terstriep, S. A., Reynolds, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00220 · Cited by 12
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience
Sadaps, M., Funchain, P., Mahdi, H., Grivas, P. D., Pritchard, A., Klek, S., Estfan, B. N., Abraham, J., Budd, G. T., Stevenson, J. P., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00186 · Cited by 10
Boussemart, L., Nelson, A., Wong, M. K., Ross, J. S., Sosman, J. A., Mehnert, J. M., Daniels, G. A., Kendra, K. L., Ali, S. M., Miller, V. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0271 · Cited by 9
Wolf, J., Han, J., Nishio, M., Souquet, P. J., Paz-Ares, L. G., de Marinis, F., Seto, T., de Jonge, M. J. A., Kim, T. M., Vansteenkiste, J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.075 · Cited by 8
Schrock, A. B., Madison, R. W., Rosenzweig, M. R., Allen, J. M., Erlich, R., Wang, S., Chidiac, T. A., Reddy, V. S., Riess, J. W., Yassa, A. E., et al. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s239675 · Cited by 4
Cited by
Swanson, K., Wu, E., Zhang, A., Alizadeh, A. A., & Zou, J. (2023) · Cell · doi:10.1016/j.cell.2023.01.035 · Cited by 597
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187
Self-citationRolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3321 · Cited by 104
Bosse, K. R., Giudice, A. M., Lane, M. V., McIntyre, B., Schürch, P. M., Pascual-Pasto, G., Buongervino, S. N., Suresh, S., Fitzsimmons, A., Hyman, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0287 · Cited by 51
Metadata
- Authors
- Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., Concepcion, A. D., Tang, Y., Bai, X., Dewal, N., Ma, P., Bailey, S. T., Thornton, J., Pavlick, D. C., Frampton, G. M., Lieber, D., White, J., Burns, C., & Vietz, C.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-03-16
- Volume
- 17
- Issue
- 3
- Pages
- e0264138
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W4220859775
- Cited by
- 376
- References
- 115
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.